Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignacio Muñoz-Sanjuan

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature|March 11, 2016
Support communities involved in disease studiesIgnacio Muñoz-Sanjuan
Handbook of Clinical Neurology|February 21, 2023
Subtyping monogenic disorders: Huntington diseaseAndrea Sturchio, Andrew P Duker, Ignacio Muñoz-Sanjuan, et al.
Journal of Biomolecular Screening|May 22, 2013
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)Dirk Winkler, Maria Beconi, Leticia M Toledo-Sherman, et al.
Journal of Biomolecular Screening|May 1, 2009
Identification of small-molecule modulators of mouse SVZ progenitor cell proliferation and differentiation through high-throughput screeningYaping Liu, Raul Lacson, Jason Cassaday, et al.
Neurobiology of Disease|February 16, 2024
Diffusion MRI marks progressive alterations in fiber integrity in the zQ175DN mouse model of Huntington's diseaseNicholas Vidas-Guscic, Joëlle van Rijswijk, Johan Van Audekerke, et al.
The Lancet. Neurology|June 18, 2022
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunitiesSarah J Tabrizi, Carlos Estevez-Fraga, Willeke M C van Roon-Mom, et al.
Journal of Biomedical Science|April 16, 2024
Longitudinal alterations in brain perfusion and vascular reactivity in the zQ175DN mouse model of Huntington's diseaseTamara Vasilkovska, Somaie Salajeghe, Verdi Vanreusel, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 InteractionJesus M Ontoria, Ilaria Biancofiore, Paola Fezzardi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature|March 11, 2016
Support communities involved in disease studiesIgnacio Muñoz-Sanjuan
Handbook of Clinical Neurology|February 21, 2023
Subtyping monogenic disorders: Huntington diseaseAndrea Sturchio, Andrew P Duker, Ignacio Muñoz-Sanjuan, et al.
Journal of Biomolecular Screening|May 22, 2013
Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)Dirk Winkler, Maria Beconi, Leticia M Toledo-Sherman, et al.
Journal of Biomolecular Screening|May 1, 2009
Identification of small-molecule modulators of mouse SVZ progenitor cell proliferation and differentiation through high-throughput screeningYaping Liu, Raul Lacson, Jason Cassaday, et al.
Neurobiology of Disease|February 16, 2024
Diffusion MRI marks progressive alterations in fiber integrity in the zQ175DN mouse model of Huntington's diseaseNicholas Vidas-Guscic, Joëlle van Rijswijk, Johan Van Audekerke, et al.
The Lancet. Neurology|June 18, 2022
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunitiesSarah J Tabrizi, Carlos Estevez-Fraga, Willeke M C van Roon-Mom, et al.
Journal of Biomedical Science|April 16, 2024
Longitudinal alterations in brain perfusion and vascular reactivity in the zQ175DN mouse model of Huntington's diseaseTamara Vasilkovska, Somaie Salajeghe, Verdi Vanreusel, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's DiseaseJohn Wityak, Michael E Prime, Frederick A Brookfield, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseMichael E Prime, Frederick A Brookfield, Stephen M Courtney, et al.
ACS Medicinal Chemistry Letters|May 22, 2020
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 InteractionJesus M Ontoria, Ilaria Biancofiore, Paola Fezzardi, et al.
Pageof 2